NO20070578L - Oral dosage forms safeguarded against abuse containing (1,2R) -3- (3-dimetylammino-l-ethyl-2-methyl-propyl) -phenol - Google Patents

Oral dosage forms safeguarded against abuse containing (1,2R) -3- (3-dimetylammino-l-ethyl-2-methyl-propyl) -phenol

Info

Publication number
NO20070578L
NO20070578L NO20070578A NO20070578A NO20070578L NO 20070578 L NO20070578 L NO 20070578L NO 20070578 A NO20070578 A NO 20070578A NO 20070578 A NO20070578 A NO 20070578A NO 20070578 L NO20070578 L NO 20070578L
Authority
NO
Norway
Prior art keywords
oral dosage
dosage form
2r
phenol
ethyl
Prior art date
Application number
NO20070578A
Other languages
Norwegian (no)
Other versions
NO337952B1 (en
Inventor
Heinrich Kugelmann
Johannes Bartholomaus
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to DE102004032103A priority Critical patent/DE102004032103A1/en
Priority to US10/890,707 priority patent/US20060039864A1/en
Priority to PCT/EP2005/006990 priority patent/WO2006002886A1/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34972022&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20070578(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of NO20070578L publication Critical patent/NO20070578L/en
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of NO337952B1 publication Critical patent/NO337952B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Abstract

Oppfinnelsen vedrører en oral doseringsform, som er sikret mot misbruk og som har en kontrollert frigivelse av (1 R, 2R)-3-(3-dimetylamino-l -etyl-2-metylpropyl)-fenol for administrering en gang daglig. The invention relates to an oral dosage form, which is secured against misuse and which has a controlled release of (1R, 2R) -3- (3-dimethylamino-l-ethyl-2-methylpropyl) -phenol for administration once daily. Oppfinnelsen er kjennetegnet ved at den orale doseringsformen innbefatter den aktive ingrediensen og/eller en eller flere farmasøytisk akseptable forbindelser (A) derav, i det minste en syntetisk og/eller naturlig polymer (C), retarderende tilsetningsstoffer, eventuelt innbefattende ytterligere fysiologiske kompatible adjuvanser (13) og innbefatter eventuelt en voks (D). The invention is characterized in that the oral dosage form comprising the active ingredient and / or one or more pharmaceutically acceptable compounds (A) thereof, at least one synthetic and / or natural polymer (C), retarding agents, optionally including additional physiological compatible adjuvants ( 13) and optionally includes a wax (D). Den orale doseringsformen har en bruddmotstand på minst 500 N, fortrinnsvis minst 750 N. Doseringsformen inneholder minst en av de følgende misbruksforhindrende bestanddelene (a)-(f); The oral dosage form has a breaking resistance of at least 500 N, preferably at least 750 N. The dosage form contains at least one of the following misbruksforhindrende components (a) - (f); (a) minst en substans som irriterer nese eller munnhulen; (A) at least one substance which irritates the nasal or oral cavity; (b) minst et viskositetsøkende middel; (B) at least one viscosity enhancing agent; (c) minst en antagonist for den aktive ingrediensen som har et misbrukspotensiale; (C) at least one antagonist for the active ingredient that have abuse potential; (d) minst et brekkmiddel; (D) at least one emetic; (e) minst et fargestoff som virker som et avskrekkende middel og; (E) at least one dye acting as a deterrent and; (f) minst en bitter substans. (F) at least one bitter substance.
NO20070578A 2004-07-01 2007-01-31 Oral dosage forms safeguarded against abuse containing (1,2R) -3- (3-dimetylammino-l-ethyl-2-methyl-propyl) -phenol NO337952B1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
DE102004032103A DE102004032103A1 (en) 2004-07-01 2004-07-01 Abuse-proofed, oral dosage form
US10/890,707 US20060039864A1 (en) 2004-07-01 2004-07-14 Abuse-proofed oral dosage form
PCT/EP2005/006990 WO2006002886A1 (en) 2004-07-01 2005-06-29 Oral dosage form safeguarded against abuse containing (1r, 2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol

Publications (2)

Publication Number Publication Date
NO20070578L true NO20070578L (en) 2007-01-31
NO337952B1 NO337952B1 (en) 2016-07-18

Family

ID=34972022

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20070578A NO337952B1 (en) 2004-07-01 2007-01-31 Oral dosage forms safeguarded against abuse containing (1,2R) -3- (3-dimetylammino-l-ethyl-2-methyl-propyl) -phenol

Country Status (9)

Country Link
EP (1) EP1786403B1 (en)
JP (1) JP5700904B2 (en)
KR (1) KR101204657B1 (en)
AR (1) AR053304A1 (en)
AU (1) AU2005259478B2 (en)
BR (1) BRPI0513300B1 (en)
CA (1) CA2572352A1 (en)
NO (1) NO337952B1 (en)
WO (1) WO2006002886A1 (en)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9629807B2 (en) 2003-08-06 2017-04-25 Grünenthal GmbH Abuse-proofed dosage form
US9636303B2 (en) 2010-09-02 2017-05-02 Gruenenthal Gmbh Tamper resistant dosage form comprising an anionic polymer
US9655853B2 (en) 2012-02-28 2017-05-23 Grünenthal GmbH Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
US9675610B2 (en) 2002-06-17 2017-06-13 Grünenthal GmbH Abuse-proofed dosage form
US9737490B2 (en) 2013-05-29 2017-08-22 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
US9750701B2 (en) 2008-01-25 2017-09-05 Grünenthal GmbH Pharmaceutical dosage form
US9855263B2 (en) 2015-04-24 2018-01-02 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
US9872835B2 (en) 2014-05-26 2018-01-23 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
US9925146B2 (en) 2009-07-22 2018-03-27 Grünenthal GmbH Oxidation-stabilized tamper-resistant dosage form
US10058548B2 (en) 2003-08-06 2018-08-28 Grünenthal GmbH Abuse-proofed dosage form
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
US10080721B2 (en) 2009-07-22 2018-09-25 Gruenenthal Gmbh Hot-melt extruded pharmaceutical dosage form
US10130591B2 (en) 2003-08-06 2018-11-20 Grünenthal GmbH Abuse-proofed dosage form
US10154966B2 (en) 2013-05-29 2018-12-18 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
US10201502B2 (en) 2011-07-29 2019-02-12 Gruenenthal Gmbh Tamper-resistant tablet providing immediate drug release
US10300141B2 (en) 2010-09-02 2019-05-28 Grünenthal GmbH Tamper resistant dosage form comprising inorganic salt

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003024429A1 (en) 2001-09-21 2003-03-27 Egalet A/S Polymer release system
EP1429744A1 (en) 2001-09-21 2004-06-23 Egalet A/S Morphine polymer release system
BRPI0309142B8 (en) 2002-04-09 2016-09-13 Flamel Ireland Ltd suspension of microcapsules in an aqueous liquid phase which allows the modified release of at least one active ingredient excluding amoxicillin and which is intended for oral administration
EP1610767B1 (en) 2003-03-26 2011-01-19 Egalet A/S Morphine controlled release system
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE102004032051A1 (en) 2004-07-01 2006-01-19 Grünenthal GmbH A process for preparing a secured against misuse, solid dosage form
FR2901478B1 (en) * 2006-05-24 2015-06-05 Flamel Tech Sa Multimicroparticulated oral pharmaceutical form with prolonged release
US9023400B2 (en) 2006-05-24 2015-05-05 Flamel Technologies Prolonged-release multimicroparticulate oral pharmaceutical form
SA2709B1 (en) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. Tamper Resistant Oral Pharmaceutical Dosage Forms Comprising an Opioid Analgesic
DE102007011485A1 (en) 2007-03-07 2008-09-11 Grünenthal GmbH Dosage form with impeded abuse
EP2155167A2 (en) 2007-06-04 2010-02-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
SI2273983T1 (en) 2008-05-09 2016-11-30 Gruenenthal Gmbh Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
NZ594207A (en) 2009-02-06 2013-03-28 Egalet Ltd Immediate release composition resistant to abuse by intake of alcohol
NZ603579A (en) 2009-06-24 2014-02-28 Egalet Ltd Controlled release formulations
US8397733B2 (en) * 2010-01-15 2013-03-19 Celanese Acetate Llc Degradable cigarette filter: pill with multilayered coating
ES2606227T3 (en) 2010-02-03 2017-03-23 Grünenthal GmbH Preparation of a pharmaceutical powder composition by an extruder
CA2832436C (en) * 2010-04-07 2018-08-14 Lupin Limited Controlled release pharmaceutical compositions of tapentadol
AU2011297954B2 (en) 2010-09-02 2014-05-15 Grunenthal Gmbh Tamper resistant dosage form comprising an anionic polymer
CA2828631A1 (en) 2011-03-04 2012-09-13 Grunenthal Gmbh Aqueous pharmaceutical formulation of tapentadol for oral administration
JP6027549B2 (en) 2011-03-04 2016-11-16 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Semi-solid aqueous pharmaceutical composition containing tapentadol
MX348831B (en) 2011-03-04 2017-06-30 Grünenthal GmbH Parenteral administration of tapentadol.
HUE034710T2 (en) 2011-07-29 2018-02-28 Gruenenthal Gmbh Tamper-resistant tablet providing immediate drug release
EP2763664A2 (en) 2011-10-06 2014-08-13 Grünenthal GmbH Tamper-resistant oral pharmaceutical dosage form comprising opioid agonist and opioid antagonist
WO2013072395A1 (en) 2011-11-17 2013-05-23 Grünenthal GmbH Tamper-resistant oral pharmaceutical dosage form comprising a pharmacologically active ingredient, an opioid antagonist and/or aversive agent, polyalkylene oxide and anionic polymer
US20130225625A1 (en) 2012-02-28 2013-08-29 Grunenthal Gmbh Tamper-resistant pharmaceutical dosage form comprising nonionic surfactant
WO2013156453A1 (en) 2012-04-18 2013-10-24 Grünenthal GmbH Tamper resistant and dose-dumping resistant pharmaceutical dosage form
MX357783B (en) 2012-05-11 2018-07-25 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc.
WO2014006004A1 (en) 2012-07-06 2014-01-09 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release
WO2014106865A1 (en) * 2013-01-07 2014-07-10 Alkem Laboratories Ltd. Abuse-proofed, extended release pharmaceutical composition comprising tapentadol or a pharmaceutically acceptable salt thereof and processes for preparing thereof
EP2808319A1 (en) 2013-05-31 2014-12-03 Arevipharma GmbH 3-[3-(Dimethylamino)-1-ethyl-2-methylpropyl]phenol resin complex
WO2015071248A1 (en) 2013-11-15 2015-05-21 Synthon B.V. Abuse-proofed extended release pharmaceutical composition comprising tapentadol
EP3073994A1 (en) 2013-11-26 2016-10-05 Grünenthal GmbH Preparation of a powdery pharmaceutical composition by means of cryo-milling
JP2016540798A (en) 2013-12-16 2016-12-28 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング A tamper resistant dosage form with a bimodal release profile produced by coextrusion
CA2947786A1 (en) 2014-05-12 2015-11-19 Grunenthal Gmbh Tamper resistant immediate release capsule formulation comprising tapentadol
EP3253376A1 (en) 2015-02-03 2017-12-13 Grünenthal GmbH Tamper-resistant dosage form comprising a polyethylene glycol graft copolymer
DK3273953T3 (en) 2015-03-27 2019-03-11 Gruenenthal Gmbh Stable formulation for parenteral administration of tapentadol
JP2018513864A (en) 2015-04-24 2018-05-31 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Tamper resistant fixed dose combination resulting in rapid release of two drugs from particles and matrix
CA2983640A1 (en) 2015-04-24 2016-10-27 Grunenthal Gmbh Tamper-resistant fixed dose combination providing fast release of two drugs from different particles
MX2017013633A (en) 2015-04-24 2018-03-08 Gruenenthal Gmbh Tamper-resistant fixed dose combination providing fast release of two drugs from particles.
KR20170003380U (en) 2016-03-21 2017-09-29 정화정 Support Apparatus For Balloon Typed Sign
US20170296476A1 (en) 2016-04-15 2017-10-19 Grünenthal GmbH Modified release abuse deterrent dosage forms
CA3029869A1 (en) 2016-07-06 2018-01-11 Grunenthal Gmbh Reinforced pharmaceutical dosage form
WO2018024709A1 (en) 2016-08-01 2018-02-08 Grünenthal GmbH Tamper resistant dosage form comprising an anionic polysaccharide
CN109862879A (en) 2016-08-12 2019-06-07 格吕伦塔尔有限公司 The anti-tamper preparation of ephedrine and its derivative
KR20190057349A (en) 2016-09-23 2019-05-28 그뤼넨탈 게엠베하 Stable formulation for parenteral administration of tapentadol
WO2018153947A1 (en) 2017-02-23 2018-08-30 Grünenthal GmbH Tapentadol as local anesthetic
WO2019073028A1 (en) 2017-10-13 2019-04-18 Grünenthal GmbH Modified release abuse deterrent dosage forms
US20190247332A1 (en) 2018-02-09 2019-08-15 Grünenthal GmbH Tamper resistant formulation of ephedrine and its derivatives comprising a conversion inhibitor

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5004601A (en) * 1988-10-14 1991-04-02 Zetachron, Inc. Low-melting moldable pharmaceutical excipient and dosage forms prepared therewith
DE69709646D1 (en) * 1996-03-12 2002-02-21 Alza Corp Composition and dosage form an opioid antagonist
US7332182B2 (en) * 2001-08-06 2008-02-19 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
US7144587B2 (en) * 2001-08-06 2006-12-05 Euro-Celtique S.A. Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent
PE05272003A1 (en) * 2001-10-24 2003-07-26 Gruenenthal Chemie Pharmaceutical formulation with delayed release that contains 3- (3-dimethylamino-1-ethyl-2-methylpropyl) phenol or a pharmaceutically acceptable salt thereof and tablets for oral administration which contain
DE10250083A1 (en) * 2002-06-17 2003-12-24 Gruenenthal Gmbh Abuse-proofed dosage form
EP1594467A4 (en) * 2002-07-05 2008-10-22 Collegium Pharmaceutical Inc Abuse-deterrent pharmaceutical compositions of opioids and other drugs
DE10250088A1 (en) * 2002-10-25 2004-05-06 Grünenthal GmbH Abuse-proofed dosage form
DE10250087A1 (en) * 2002-10-25 2004-05-06 Grünenthal GmbH Abuse-proofed dosage form
DE10250084A1 (en) * 2002-10-25 2004-05-06 Grünenthal GmbH Abuse-proofed dosage form

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10369109B2 (en) 2002-06-17 2019-08-06 Grünenthal GmbH Abuse-proofed dosage form
US9675610B2 (en) 2002-06-17 2017-06-13 Grünenthal GmbH Abuse-proofed dosage form
US10130591B2 (en) 2003-08-06 2018-11-20 Grünenthal GmbH Abuse-proofed dosage form
US10058548B2 (en) 2003-08-06 2018-08-28 Grünenthal GmbH Abuse-proofed dosage form
US9629807B2 (en) 2003-08-06 2017-04-25 Grünenthal GmbH Abuse-proofed dosage form
US9750701B2 (en) 2008-01-25 2017-09-05 Grünenthal GmbH Pharmaceutical dosage form
US9925146B2 (en) 2009-07-22 2018-03-27 Grünenthal GmbH Oxidation-stabilized tamper-resistant dosage form
US10080721B2 (en) 2009-07-22 2018-09-25 Gruenenthal Gmbh Hot-melt extruded pharmaceutical dosage form
US9636303B2 (en) 2010-09-02 2017-05-02 Gruenenthal Gmbh Tamper resistant dosage form comprising an anionic polymer
US10300141B2 (en) 2010-09-02 2019-05-28 Grünenthal GmbH Tamper resistant dosage form comprising inorganic salt
US10201502B2 (en) 2011-07-29 2019-02-12 Gruenenthal Gmbh Tamper-resistant tablet providing immediate drug release
US9655853B2 (en) 2012-02-28 2017-05-23 Grünenthal GmbH Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
US10154966B2 (en) 2013-05-29 2018-12-18 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
US9737490B2 (en) 2013-05-29 2017-08-22 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
US9872835B2 (en) 2014-05-26 2018-01-23 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
US9855263B2 (en) 2015-04-24 2018-01-02 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction

Also Published As

Publication number Publication date
EP1786403A1 (en) 2007-05-23
AU2005259478B2 (en) 2010-07-15
KR101204657B1 (en) 2012-11-27
KR20070039041A (en) 2007-04-11
EP1786403B1 (en) 2013-07-24
AR053304A1 (en) 2007-05-02
CA2572352A1 (en) 2006-01-12
BRPI0513300A (en) 2008-05-06
NO337952B1 (en) 2016-07-18
WO2006002886A1 (en) 2006-01-12
JP5700904B2 (en) 2015-04-15
JP2008504328A (en) 2008-02-14
AU2005259478A1 (en) 2006-01-12
BRPI0513300B1 (en) 2018-11-06

Similar Documents

Publication Publication Date Title
KR100481254B1 (en) A pharmaceutical composition comprising the mirtazapine and one or more selective serotonin reuptake inhibitors
Benfield et al. Fluvoxamine
CN100548290C (en) Use of sulfamate derivative for treating impulse control disorders
RU2202344C2 (en) Nociceptine antagonists, amide derivatives, analgetic agent, method of initiation of antagonistic effect to nociceptine, method of pain treatment, pharmaceutical compositions
RU2227022C2 (en) Bioadhesive buccal sustained-release tablet
RU2396980C2 (en) Method of treating lupous
RU2219926C2 (en) Antioxidant-containing percutaneous therapeutic system
AU2002316582B2 (en) Oral administration of 6-hydroxy-oxymorphone for use as an analgesic
RU2201231C2 (en) Compositions and methods of attenuation of respiratory depression and accompanying adverse effects of mu-opioid compounds
RU2314810C2 (en) Method for treatment using medicinal formulations containing pharmaceutical compositions of 5,8,14,-triazatetracyclo[10.3.1.0 (2,11).0(4,9)]hexadeca-2( 11),3,5,7,9-pentaene
NO334743B1 (en) Pump-action liquid spray formulation
NO20100250L (en) Pharmaceutical compositions comprising a S1P receptor agonist and a sugar alcohol, and progress feed for the preparation thereof
WO2001001973A8 (en) Highly selective norepinephrine reuptake inhibitors and methods of using the same
AR022008A1 (en) A controlled release composition of galanthamine, a process for preparing the same, and the use of said composition for the preparation of a medicament
CA2529746A1 (en) Oral extended-release composition
NO20043702L (en) 8 azaprostaglandinderivatforbindelser and medicines containing the compounds as the active ingredient
RU2321423C2 (en) Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
NO20062181L (en) Method for preparing aminokrotonylforbindelser
BR0316906A (en) administration of capsaicinoids
NO20025601D0 (en) Arylmetylaminderivater for use as tryptaseinhibitorer
NO324440B1 (en) Quinazolinones, use of these compounds as medicament and pharmaceutical compositions using these compounds for preparing medicaments for treating diseases and an in vitro method of inhibiting KSP kinesin-based on such compounds
BR0107869A (en) Pharmaceutical compositions eletrogiradas
FR2858931B1 (en) Device for oral administration of a drug
MY144992A (en) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives.
NO328053B1 (en) Condensed pyridazinderivatforbindelser and medicines containing the compounds as the active ingredient